title: Effects of suspending ACE inhibitors and ARBs in advanced chronic kidney disease.
authors.forename: Martha E
authors.initials: ME
authors.lastname: Díaz-Domínguez
authors.forename: Milagros
authors.initials: M
authors.lastname: Fernández-Lucas
authors.forename: Antonio
authors.initials: A
authors.lastname: Gomis-Couto
authors.forename: Gloria
authors.initials: G
authors.lastname: Ruiz-Roso
authors.forename: José L
authors.initials: JL
authors.lastname: Teruel
authors.forename: Carlos
authors.initials: C
authors.lastname: Quereda
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D057911:Angiotensin Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000150:complications; D057915:Drug Substitution; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D007674:Kidney Diseases / Q000150:complications; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000188:drug therapy / Q000209:etiology; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers